Friends Of Cancer Research, ACS CAN Urge Congress To Pass VALID

Two leading cancer research advocacy groups are calling on Congress to pass a key diagnostics reform bill, arguing that laboratory-developed tests (LDTs) used to determine treatment for cancer patients are not regulated closely enough and lead to unreliable test results that can impede access to safe and effective treatment. Lisa Lacasse, president of the American Cancer Society Cancer Action Network and Jeff Allen, president and CEO of Friends of Cancer Research, wrote in an op-ed published in STAT Wednesday...